BonGeo Pharmaceuticals, Inc. – Trademark Portfolio

Entity Type: 03

BonGeo Pharmaceuticals, Inc. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. Currently, 4 trademarks are registered. Notable registered marks include MULTIA, FLORIVA, INFANA-D, and TENDERA-OB. The owner is based in Roseland, NJ.

101 Eisenhower Parkway, Suite 300

Roseland, NJ 07068

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

MULTIA
MULTIA
Registered 2022
INFANA-D
INFANA-D
Registered 2019
NATUSSA
NATUSSA
Cancelled 2019
FLORIVA
FLORIVA
Registered 2014

Trademark Classifications

BonGeo Pharmaceuticals, Inc.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (5 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does BonGeo Pharmaceuticals, Inc. have?

BonGeo Pharmaceuticals, Inc. has 5 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 cancelled.

What trademark classes does BonGeo Pharmaceuticals, Inc. file in?

BonGeo Pharmaceuticals, Inc. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are BonGeo Pharmaceuticals, Inc.'s most well-known trademarks?

BonGeo Pharmaceuticals, Inc.'s registered trademark portfolio includes well-known marks such as MULTIA, FLORIVA, INFANA-D, and TENDERA-OB. These are among 4 currently registered trademarks in the portfolio.

What is BonGeo Pharmaceuticals, Inc.'s trademark registration success rate?

BonGeo Pharmaceuticals, Inc. has a 80% trademark registration rate, with 4 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.